Royalty Report: Medical, Device, Therapeutic – Collection: 27563


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 5


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5

Primary Industries

  • Medical
  • Device
  • Therapeutic
  • Stroke treatment
  • Drugs
  • Disease
  • Alzheimer’s disease
  • Kidneys
  • Surgical
  • Ophthalmological

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 27563

License Grant
The purchased assets include intellectual property and licenses.
License Property
The Licensor is engaged, inter alia, in the development and commercialization of a laser Thrombolysis system for the treatment of acute ischemic stroke.

'Stroke Disposable(s)' means a single use medical device utilizing laser energy in the treatment of ischemic stroke in humans that has achieved its first regulatory approval for such use.

IPSCIO Record ID: 240607

License Grant
The License Agreement, between the Licensor and the Swedish Licensee, is hereby amended so as to remove any Co-Promote rights for Licensor for any Licensed Product.
License Property
The compounds relate to the Alzheimers Project and Stroke Project.

Alzheimers Project Licensed Product means a product incorporating as an active ingredient a compound which is a spin trapping agent, derivative or composition thereof used as a free radical scavenger, for the treatment of Alzheimers disease.

Stroke Project Licensed Product, including a compound known as NXY-059 means a product incorporating as an active ingredient a compound based upon using spin trapping agents and
derivatives and compositions thereof as free radical scavengers, for acute treatment of stroke, and, prophylactic treatment of stroke, head trauma, multi-infarct dementia, and pain associated with stroke, as further specified in the R&D Plans.

Field of Use
The stroke project is used as free radical scavengers and/or therapeutics for acute treatment of stroke, prophylactic treatment of stroke, head trauma, multi-infarct dementia, and pain associated with stroke, as further specified in the R&D Plans.

IPSCIO Record ID: 253474

License Grant
In this related party agreement, the Canadian Licensor grants Licensee exclusive rights to develop and commercialize DM199 for acute ischemic stroke in mainland China, Taiwan, Hong Kong S.A.R. and Macau S.A.R
License Property
DM199 is a recombinant form of human tissue kallikrein-1 (“KLK1”). KLK1 is an endogenous serine protease (protein) produced in the kidneys, pancreas and salivary glands, which plays a critical role in the regulation of local blood flow and vasodilation (the widening of blood vessels which decreases blood pressure) in the body, as well as an important role in managing inflammation and oxidative stress (an imbalance between potentially damaging reactive oxygen species, or free radicals, and antioxidants in your body). The Company believes DM199 has the potential to treat a variety of diseases where healthy functioning requires sufficient activity of KLK1 and its biochemical system, the kallikrein-kinin system (“KKS”).
Field of Use
This agreement pertains to the drug industry relating to treatment of neurological and kidney diseases focusing on acute ischemic stroke (“AIS”) and chronic kidney disease (“CKD”).

IPSCIO Record ID: 375426

License Grant
The Licensee acquired certain intellectual property from an undisclosed Licensor to be used in the development of the ALLY Adaptive Cataract Treatment System.
License Property
ALLY Adaptive Cataract Treatment System is designed to combine our existing femtosecond laser technology with enhanced capabilities and a phacoemulsification system into a single unit and allow surgeons to perform each of the critical steps in a cataract procedure in a single operating room using this device.
Field of Use
The rights acquired are for laser technology in a device used by medical surgeons in a cataract procedure.

IPSCIO Record ID: 1975

License Grant
The Company licensed it intellectual laser properties; patented ultrafast laser systems for the treatment of a broad range of eye disorders.
License Property
Licensor’s solid-state pico-second (one trillionth of a second) Nd YLF (NeodymiumYitrium-Lithium-Fluoride) laser systems are designed to be more precise than lasers systems utilizing currently available technologies.
Field of Use
The rights granted apply to the healthcare market specializing in ophthalmic medical devices.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.